Search

Your search keyword '"RIZZI, SIMONA"' showing total 141 results

Search Constraints

Start Over You searched for: Author "RIZZI, SIMONA" Remove constraint Author: "RIZZI, SIMONA"
141 results on '"RIZZI, SIMONA"'

Search Results

1. Novel Thienoduocarmycin–Trastuzumab ADC Demonstrates Strong Antitumor Efficacy with Favorable Safety Profile in Preclinical Studies

3. Data from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

4. Supplementary Figures 1-8 from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

5. Supplementary Methods, Figure Legends 1-8, Tables 1-4 from NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

7. Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, and Real-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis

10. Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: identification of risk categories according to number of positive nodes and Gleason score

14. An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma

20. Abstract 734: Thienoindoles: New highly promising agents for antibody-drug conjugates generation

22. Abstract 5163: Characterization of NMS-E194, a selective and potent PERK inhibitor with efficacy in the KMS-11 multiple myeloma

23. Survival, continence and potency (SCP) recovery after radical retropubic prostatectomy: A long-term combined evaluation of surgical outcomes

24. [Predictors of positive surgical margins after nephron-sparing surgery for renal cell carcinoma: retrospective analysis on 298 consecutive patients]

25. Abstract 2690: A novel antibody-drug conjugate directed to the ALK receptor tyrosine kinase demonstrates efficacy in models of neuroblastoma

26. THE PROGNOSTIC IMPACT OF TUMOR SIZE ON CANCER-SPECIFIC AND OVERALL SURVIVAL AMONG PATIENTS WITH PATHOLOGIC T3A RENAL CELL CARCINOMA

27. VALIDATION OF PRIAS ACTIVE SURVEILLANCE CRITERIA IN PATIENTS SUBMITED TO RADICAL PROSTATECTOMY

28. In patients with pathologically positive lymph nodes, three positive nodes represent a significant and independent cut-point for cancer-specific and overall survival

29. RUOLO DELLA LYMPH-NODE DENSITY NELL’OUTCOME ONCOLOGICO DEI PAZIENTI CON METASTASI LINFONODALI DA CARCINOMA prostatico SOTTOPOSTI A PROSTATECTOMIA RADICALE E LINFADENECTOMIA PELVICA

30. Nodal Occult Metastases in Intermediate- and High-Risk Prostate Cancer Patients Detected Using Serial Section, Immunohistochemistry, and Real-Time Reverse Transcriptase Polymerase Chain Reaction: Prospective Evaluation With Matched-Pair Analysis

31. Abstract A149: NMS-P945, a highly active payload for antibody drug conjugates generation

32. Effects of environmental complexity on neurogenesis in the hippocampal dentate gyrus

33. Neonatal isolation impairs neurogenesis in the dentate gyrus of the guinea pig

35. Discovery of 2-(Cyclohexylmethylamino)pyrimidines as a New Class of Reversible Valosine Containing Protein Inhibitors

36. Abstract 822: Thienoindoles, a novel class of DNA minor groove alkylating agents highly suited for the generation of novel antibody drug conjugates (ADCs)

38. Effects of environmental complexity on neurogenesis in the hippocampal dentate gyrus

39. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death

40. Alkylsulfanyl-1,2,4-triazoles, a New Class of Allosteric Valosine Containing Protein Inhibitors. Synthesis and Structure–Activity Relationships

41. NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

42. Abstract 2940: Identification of potent VCP/p97/CDC48 inhibitors with distinct biochemical mechanisms including a reversible, allosteric inhibitor that activates the unfolded protein response, induce autophagy and cancer cell death

44. Phase I-II Trial of Adoptive Immunotherapy with Haploidentical KIR Ligand-Mismatched Natural Killer Cells in High Risk Acute Myeloblastic Leukemia Patients.

48. Discovery of 2-(Cyclohexylmethylamino)pyrimidinesas a New Class of Reversible Valosine Containing Protein Inhibitors.

50. Redundancy of autocrine loops in human osteosarcoma cells

Catalog

Books, media, physical & digital resources